Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions
Condition: Healthy
Intervention: Moexipril HCl/hydrochlorothiazide 15/25 mg tablets; UNIRETIC® 15/25 mg tablets
Intervention description: 1 x 15/25 mg; 1 x 15/25 mg
Intervention MeSH terms: Hydrochlorothiazide; Moexipril
Phase: Phase 1
Study type: Interventional
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Enrollment: 60.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Bioequivalence; Healthy Subjects

Summary:

      The objective of this study is to compare the relative bioavailability of moexipril HCl/
      hydrochlorothiazide 15/25 mg tablets (manufactured and distributed by TEVA Pharmaceuticals
      USA) with that of UNIRETIC® 15/25 mg tablets (Schwartz Pharma) in healthy, adult, non-smoking
      subjects under non-fasting conditions.
    

Eligibility criteria:

        Inclusion Criteria:

          -  All subjects selected for this study will be non-smokers at least 18 years of age.

          -  Subjects will have a BMI index (body mass index) of 30 or less.

        Exclusion Criteria:

          -  Subjects with a history of chronic alcohol consumption (during past 2 years), drug
             addiction, or serious gastrointestinal, renal, hepatic, tuberculosis, epilepsy, asthma
             (during past 5 years), diabetes, psychosis or glaucoma will not be eligible for this
             study.

          -  Subjects whose clinical laboratory test values are greater than 20% outside the normal
             range may be retested. If the clinical values are outside the range on retesting, the
             subject will not be eligible to participate in the study unless the clinical
             investigator deems the result not to be significant.

          -  Subjects who have a history of allergic responses to the class of drug being tested
             should be excluded from the study.

          -  All subjects will have urine samples assayed for the presence of abuse as part of the
             clinical laboratory screening procedures and ath check-in each study period. Subjects
             found to have urine concentrations of any of the tested drug will not be allowed to
             participate.

          -  Subjects should not have donated blood and/or plasma for at least thirty (30) days
             prior to the first dosing of the study.

          -  Subjects who have taken an investigational drug within thirty (30) days prior to the
             first dosing of the study will not be allowed to participate.

          -  Female subjects who are pregnant, breast-feeding, or who are likely to become pregnant
             during the study will not be allowed to participate. Female subjects of child bearing
             potential must either abstain from sexual intercourse or use a reliable barrier method
             (e.g. condom, IUD) of contraception during the course of the study (first dosing until
             last blood collection) or they will not be allowed to participate. Subjects who have
             used implanted or injected hormonal contraceptives anytime during the 180 days prior
             to study dosing or oral hormonal contraceptives with in 14 days of dosing will not be
             allowed to participate.

          -  All female subjects will be screened for pregnancy at check-in each study period.
             Subjects with positive or inconclusive results will be withdrawn from the study.

          -  Subjects who use tobacco in any form will not be eligible to participate in the study.
             Three months abstinence is required.

          -  Subjects who do not tolerate venipuncture will not be allowed to participate.